Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,024
archived clinical trials in
Infectious Disease

Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Meropenem in Complicated Intraabdominal Infections
A Multicenter, Double-Blind, Randomized, Phase 3 Study to Compare the Efficacy and Safety of Intravenous CXA-201 With That of Meropenem in Complicated Intraabdominal Infections
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Columbus, OH
Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Meropenem in Complicated Intraabdominal Infections
A Multicenter, Double-Blind, Randomized, Phase 3 Study to Compare the Efficacy and Safety of Intravenous CXA-201 With That of Meropenem in Complicated Intraabdominal Infections
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Meropenem in Complicated Intraabdominal Infections
A Multicenter, Double-Blind, Randomized, Phase 3 Study to Compare the Efficacy and Safety of Intravenous CXA-201 With That of Meropenem in Complicated Intraabdominal Infections
Status: Enrolling
Updated:  12/31/1969
mi
from
Ciudadelo-Buenos Aires,
Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Meropenem in Complicated Intraabdominal Infections
A Multicenter, Double-Blind, Randomized, Phase 3 Study to Compare the Efficacy and Safety of Intravenous CXA-201 With That of Meropenem in Complicated Intraabdominal Infections
Status: Enrolling
Updated: 12/31/1969
mi
from
Ciudadelo-Buenos Aires,
Click here to add this to my saved trials
The Skin Prep Study
Antiseptic Skin Preparation for Preventing Surgical Site Infection at Cesarean Delivery: a Randomized Comparative Effectiveness Trial
Status: Enrolling
Updated:  12/31/1969
Barnes Jewish Hospital
mi
from
Saint Louis, MO
The Skin Prep Study
Antiseptic Skin Preparation for Preventing Surgical Site Infection at Cesarean Delivery: a Randomized Comparative Effectiveness Trial
Status: Enrolling
Updated: 12/31/1969
Barnes Jewish Hospital
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Effects of Oral Probiotic Supplementation on Group B Strep (GBS) Rectovaginal Colonization in Pregnancy
Oral Probiotic Supplementation and Group B Streptococcus Rectovaginal Colonization in Pregnant Women: a Randomized Double-blind Placebo-controlled Trial.
Status: Enrolling
Updated:  12/31/1969
Aptos Women's Health Center
mi
from
Aptos, CA
Effects of Oral Probiotic Supplementation on Group B Strep (GBS) Rectovaginal Colonization in Pregnancy
Oral Probiotic Supplementation and Group B Streptococcus Rectovaginal Colonization in Pregnant Women: a Randomized Double-blind Placebo-controlled Trial.
Status: Enrolling
Updated: 12/31/1969
Aptos Women's Health Center
mi
from
Aptos, CA
Click here to add this to my saved trials
Effects of Oral Probiotic Supplementation on Group B Strep (GBS) Rectovaginal Colonization in Pregnancy
Oral Probiotic Supplementation and Group B Streptococcus Rectovaginal Colonization in Pregnant Women: a Randomized Double-blind Placebo-controlled Trial.
Status: Enrolling
Updated:  12/31/1969
Dominican Hospital
mi
from
Santa Cruz, CA
Effects of Oral Probiotic Supplementation on Group B Strep (GBS) Rectovaginal Colonization in Pregnancy
Oral Probiotic Supplementation and Group B Streptococcus Rectovaginal Colonization in Pregnant Women: a Randomized Double-blind Placebo-controlled Trial.
Status: Enrolling
Updated: 12/31/1969
Dominican Hospital
mi
from
Santa Cruz, CA
Click here to add this to my saved trials
Effects of Oral Probiotic Supplementation on Group B Strep (GBS) Rectovaginal Colonization in Pregnancy
Oral Probiotic Supplementation and Group B Streptococcus Rectovaginal Colonization in Pregnant Women: a Randomized Double-blind Placebo-controlled Trial.
Status: Enrolling
Updated:  12/31/1969
Stanford University School of Medicine, Lucile Packard Children's Hospital
mi
from
Stanford, CA
Effects of Oral Probiotic Supplementation on Group B Strep (GBS) Rectovaginal Colonization in Pregnancy
Oral Probiotic Supplementation and Group B Streptococcus Rectovaginal Colonization in Pregnant Women: a Randomized Double-blind Placebo-controlled Trial.
Status: Enrolling
Updated: 12/31/1969
Stanford University School of Medicine, Lucile Packard Children's Hospital
mi
from
Stanford, CA
Click here to add this to my saved trials
Administration of Donor T Cells With the Caspase-9 Suicide Gene
Administration of Haploidentical Donor T Cells Transduced With the Inducible Caspase-9 Suicide Gene
Status: Enrolling
Updated:  12/31/1969
Texas Children's Hospital
mi
from
Houston, TX
Administration of Donor T Cells With the Caspase-9 Suicide Gene
Administration of Haploidentical Donor T Cells Transduced With the Inducible Caspase-9 Suicide Gene
Status: Enrolling
Updated: 12/31/1969
Texas Children's Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Administration of Donor T Cells With the Caspase-9 Suicide Gene
Administration of Haploidentical Donor T Cells Transduced With the Inducible Caspase-9 Suicide Gene
Status: Enrolling
Updated:  12/31/1969
Methodist Hospital
mi
from
Houston, TX
Administration of Donor T Cells With the Caspase-9 Suicide Gene
Administration of Haploidentical Donor T Cells Transduced With the Inducible Caspase-9 Suicide Gene
Status: Enrolling
Updated: 12/31/1969
Methodist Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies
A Phase II Study of the Therapeutic Effects Of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies
A Phase II Study of the Therapeutic Effects Of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Respiratory Syncytial Virus - RSV Protocol
An Open Label Randomized Controlled Trial To Prevent the Progression of Respiratory Syncytial Virus Upper Respiratory Tract Infection to Lower Respiratory Tract Infection in Patients After Hematopoietic Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Respiratory Syncytial Virus - RSV Protocol
An Open Label Randomized Controlled Trial To Prevent the Progression of Respiratory Syncytial Virus Upper Respiratory Tract Infection to Lower Respiratory Tract Infection in Patients After Hematopoietic Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Intrapleural Measles Virus Therapy in Patients With Malignant Pleural Mesothelioma
A Phase 1 Trial of Oncolytic Measles Virotherapy in Mesothelioma
Status: Enrolling
Updated:  12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Intrapleural Measles Virus Therapy in Patients With Malignant Pleural Mesothelioma
A Phase 1 Trial of Oncolytic Measles Virotherapy in Mesothelioma
Status: Enrolling
Updated: 12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Inflammation, Viral Replication, and Atherosclerosis in Treated HIV Infection
Immunologic and Inflammatory Factors and Cardiovascular Risk in Patients With HIV Infection or Autoimmune Diseases
Status: Enrolling
Updated:  12/31/1969
University of California, San Francisco, San Francisco General Hospital
mi
from
San Francisco, CA
Inflammation, Viral Replication, and Atherosclerosis in Treated HIV Infection
Immunologic and Inflammatory Factors and Cardiovascular Risk in Patients With HIV Infection or Autoimmune Diseases
Status: Enrolling
Updated: 12/31/1969
University of California, San Francisco, San Francisco General Hospital
mi
from
San Francisco, CA
Click here to add this to my saved trials
Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies
A Phase I Study of CD8 Memory T-Cell Donor Lymphocyte Infusion for Relapse of Hematolymphoid Malignancies Following Matched Related Donor Allogeneic Hematopoietic Cell Transplantation
Status: Enrolling
Updated:  12/31/1969
Stanford University
mi
from
Stanford, CA
Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies
A Phase I Study of CD8 Memory T-Cell Donor Lymphocyte Infusion for Relapse of Hematolymphoid Malignancies Following Matched Related Donor Allogeneic Hematopoietic Cell Transplantation
Status: Enrolling
Updated: 12/31/1969
Stanford University
mi
from
Stanford, CA
Click here to add this to my saved trials
Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
A Phase II Trial of Reduced Intensity Allogeneic Stem Cell Transplantation With Fludarabine, Melphalan and Low Dose Total Body Irradiation
Status: Enrolling
Updated:  12/31/1969
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
A Phase II Trial of Reduced Intensity Allogeneic Stem Cell Transplantation With Fludarabine, Melphalan and Low Dose Total Body Irradiation
Status: Enrolling
Updated: 12/31/1969
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Furlow Palatoplasty With Tensor Tenopexy
Furlow Palatoplasty With Tensor Tenopexy for Otitis Media
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Furlow Palatoplasty With Tensor Tenopexy
Furlow Palatoplasty With Tensor Tenopexy for Otitis Media
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Sevelamer for Reducing Endotoxemia and Immune Activation
Sevelamer Carbonate for Reducing Endotoxemia and Immune Activation: A Proof of Concept Study
Status: Enrolling
Updated:  12/31/1969
Alabama Therapeutics CRS (5801)
mi
from
Birmingham, AL
Sevelamer for Reducing Endotoxemia and Immune Activation
Sevelamer Carbonate for Reducing Endotoxemia and Immune Activation: A Proof of Concept Study
Status: Enrolling
Updated: 12/31/1969
Alabama Therapeutics CRS (5801)
mi
from
Birmingham, AL
Click here to add this to my saved trials
Sevelamer for Reducing Endotoxemia and Immune Activation
Sevelamer Carbonate for Reducing Endotoxemia and Immune Activation: A Proof of Concept Study
Status: Enrolling
Updated:  12/31/1969
UCLA CARE Center CRS (601)
mi
from
Los Angeles, CA
Sevelamer for Reducing Endotoxemia and Immune Activation
Sevelamer Carbonate for Reducing Endotoxemia and Immune Activation: A Proof of Concept Study
Status: Enrolling
Updated: 12/31/1969
UCLA CARE Center CRS (601)
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Sevelamer for Reducing Endotoxemia and Immune Activation
Sevelamer Carbonate for Reducing Endotoxemia and Immune Activation: A Proof of Concept Study
Status: Enrolling
Updated:  12/31/1969
University of Colorado Hospital CRS (6101)
mi
from
Aurora, CO
Sevelamer for Reducing Endotoxemia and Immune Activation
Sevelamer Carbonate for Reducing Endotoxemia and Immune Activation: A Proof of Concept Study
Status: Enrolling
Updated: 12/31/1969
University of Colorado Hospital CRS (6101)
mi
from
Aurora, CO
Click here to add this to my saved trials
Sevelamer for Reducing Endotoxemia and Immune Activation
Sevelamer Carbonate for Reducing Endotoxemia and Immune Activation: A Proof of Concept Study
Status: Enrolling
Updated:  12/31/1969
Northwestern University CRS (2701)
mi
from
Chicago, IL
Sevelamer for Reducing Endotoxemia and Immune Activation
Sevelamer Carbonate for Reducing Endotoxemia and Immune Activation: A Proof of Concept Study
Status: Enrolling
Updated: 12/31/1969
Northwestern University CRS (2701)
mi
from
Chicago, IL
Click here to add this to my saved trials
Sevelamer for Reducing Endotoxemia and Immune Activation
Sevelamer Carbonate for Reducing Endotoxemia and Immune Activation: A Proof of Concept Study
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital ACTG CRS (101)
mi
from
Boston, MA
Sevelamer for Reducing Endotoxemia and Immune Activation
Sevelamer Carbonate for Reducing Endotoxemia and Immune Activation: A Proof of Concept Study
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital ACTG CRS (101)
mi
from
Boston, MA
Click here to add this to my saved trials
Sevelamer for Reducing Endotoxemia and Immune Activation
Sevelamer Carbonate for Reducing Endotoxemia and Immune Activation: A Proof of Concept Study
Status: Enrolling
Updated:  12/31/1969
AIDS Care CRS (1108)
mi
from
Rochester, NY
Sevelamer for Reducing Endotoxemia and Immune Activation
Sevelamer Carbonate for Reducing Endotoxemia and Immune Activation: A Proof of Concept Study
Status: Enrolling
Updated: 12/31/1969
AIDS Care CRS (1108)
mi
from
Rochester, NY
Click here to add this to my saved trials
Sevelamer for Reducing Endotoxemia and Immune Activation
Sevelamer Carbonate for Reducing Endotoxemia and Immune Activation: A Proof of Concept Study
Status: Enrolling
Updated:  12/31/1969
University of Rochester ACTG CRS (1101)
mi
from
Rochester, NY
Sevelamer for Reducing Endotoxemia and Immune Activation
Sevelamer Carbonate for Reducing Endotoxemia and Immune Activation: A Proof of Concept Study
Status: Enrolling
Updated: 12/31/1969
University of Rochester ACTG CRS (1101)
mi
from
Rochester, NY
Click here to add this to my saved trials
Sevelamer for Reducing Endotoxemia and Immune Activation
Sevelamer Carbonate for Reducing Endotoxemia and Immune Activation: A Proof of Concept Study
Status: Enrolling
Updated:  12/31/1969
Univ. of Cincinnati CRS (2401)
mi
from
Cincinnati, OH
Sevelamer for Reducing Endotoxemia and Immune Activation
Sevelamer Carbonate for Reducing Endotoxemia and Immune Activation: A Proof of Concept Study
Status: Enrolling
Updated: 12/31/1969
Univ. of Cincinnati CRS (2401)
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Sevelamer for Reducing Endotoxemia and Immune Activation
Sevelamer Carbonate for Reducing Endotoxemia and Immune Activation: A Proof of Concept Study
Status: Enrolling
Updated:  12/31/1969
Case CRS (2501)
mi
from
Cleveland, OH
Sevelamer for Reducing Endotoxemia and Immune Activation
Sevelamer Carbonate for Reducing Endotoxemia and Immune Activation: A Proof of Concept Study
Status: Enrolling
Updated: 12/31/1969
Case CRS (2501)
mi
from
Cleveland, OH
Click here to add this to my saved trials
Sevelamer for Reducing Endotoxemia and Immune Activation
Sevelamer Carbonate for Reducing Endotoxemia and Immune Activation: A Proof of Concept Study
Status: Enrolling
Updated:  12/31/1969
Metro Health CRS (2503)
mi
from
Cleveland, OH
Sevelamer for Reducing Endotoxemia and Immune Activation
Sevelamer Carbonate for Reducing Endotoxemia and Immune Activation: A Proof of Concept Study
Status: Enrolling
Updated: 12/31/1969
Metro Health CRS (2503)
mi
from
Cleveland, OH
Click here to add this to my saved trials
Sevelamer for Reducing Endotoxemia and Immune Activation
Sevelamer Carbonate for Reducing Endotoxemia and Immune Activation: A Proof of Concept Study
Status: Enrolling
Updated:  12/31/1969
Hosp. of the Univ. of Pennsylvania CRS (6201)
mi
from
Philadelphia, PA
Sevelamer for Reducing Endotoxemia and Immune Activation
Sevelamer Carbonate for Reducing Endotoxemia and Immune Activation: A Proof of Concept Study
Status: Enrolling
Updated: 12/31/1969
Hosp. of the Univ. of Pennsylvania CRS (6201)
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Sevelamer for Reducing Endotoxemia and Immune Activation
Sevelamer Carbonate for Reducing Endotoxemia and Immune Activation: A Proof of Concept Study
Status: Enrolling
Updated:  12/31/1969
Ucsf Aids Crs (801)
mi
from
San Francisco, CA
Sevelamer for Reducing Endotoxemia and Immune Activation
Sevelamer Carbonate for Reducing Endotoxemia and Immune Activation: A Proof of Concept Study
Status: Enrolling
Updated: 12/31/1969
Ucsf Aids Crs (801)
mi
from
San Francisco, CA
Click here to add this to my saved trials
Sevelamer for Reducing Endotoxemia and Immune Activation
Sevelamer Carbonate for Reducing Endotoxemia and Immune Activation: A Proof of Concept Study
Status: Enrolling
Updated:  12/31/1969
Harbor-UCLA Med. Ctr. CRS (603)
mi
from
Torrance, CA
Sevelamer for Reducing Endotoxemia and Immune Activation
Sevelamer Carbonate for Reducing Endotoxemia and Immune Activation: A Proof of Concept Study
Status: Enrolling
Updated: 12/31/1969
Harbor-UCLA Med. Ctr. CRS (603)
mi
from
Torrance, CA
Click here to add this to my saved trials
Sevelamer for Reducing Endotoxemia and Immune Activation
Sevelamer Carbonate for Reducing Endotoxemia and Immune Activation: A Proof of Concept Study
Status: Enrolling
Updated:  12/31/1969
University of Miami AIDS CRS (901)
mi
from
Miami, FL
Sevelamer for Reducing Endotoxemia and Immune Activation
Sevelamer Carbonate for Reducing Endotoxemia and Immune Activation: A Proof of Concept Study
Status: Enrolling
Updated: 12/31/1969
University of Miami AIDS CRS (901)
mi
from
Miami, FL
Click here to add this to my saved trials
Sevelamer for Reducing Endotoxemia and Immune Activation
Sevelamer Carbonate for Reducing Endotoxemia and Immune Activation: A Proof of Concept Study
Status: Enrolling
Updated:  12/31/1969
Washington University CRS (2101)
mi
from
Saint Louis, MO
Sevelamer for Reducing Endotoxemia and Immune Activation
Sevelamer Carbonate for Reducing Endotoxemia and Immune Activation: A Proof of Concept Study
Status: Enrolling
Updated: 12/31/1969
Washington University CRS (2101)
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children
Study to Determine Protective Efficacy Against Otitis Media and Assess Safety of an Investigational Pneumococcal Vaccine 2189242A in Healthy Infants
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Chinle, AZ
Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children
Study to Determine Protective Efficacy Against Otitis Media and Assess Safety of an Investigational Pneumococcal Vaccine 2189242A in Healthy Infants
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Chinle, AZ
Click here to add this to my saved trials
Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children
Study to Determine Protective Efficacy Against Otitis Media and Assess Safety of an Investigational Pneumococcal Vaccine 2189242A in Healthy Infants
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Fort Defiance, AZ
Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children
Study to Determine Protective Efficacy Against Otitis Media and Assess Safety of an Investigational Pneumococcal Vaccine 2189242A in Healthy Infants
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Fort Defiance, AZ
Click here to add this to my saved trials
Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children
Study to Determine Protective Efficacy Against Otitis Media and Assess Safety of an Investigational Pneumococcal Vaccine 2189242A in Healthy Infants
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Whiteriver, AZ
Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children
Study to Determine Protective Efficacy Against Otitis Media and Assess Safety of an Investigational Pneumococcal Vaccine 2189242A in Healthy Infants
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Whiteriver, AZ
Click here to add this to my saved trials
Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children
Study to Determine Protective Efficacy Against Otitis Media and Assess Safety of an Investigational Pneumococcal Vaccine 2189242A in Healthy Infants
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Gallup, NM
Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children
Study to Determine Protective Efficacy Against Otitis Media and Assess Safety of an Investigational Pneumococcal Vaccine 2189242A in Healthy Infants
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Gallup, NM
Click here to add this to my saved trials
Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children
Study to Determine Protective Efficacy Against Otitis Media and Assess Safety of an Investigational Pneumococcal Vaccine 2189242A in Healthy Infants
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Shiprock, NM
Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children
Study to Determine Protective Efficacy Against Otitis Media and Assess Safety of an Investigational Pneumococcal Vaccine 2189242A in Healthy Infants
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Shiprock, NM
Click here to add this to my saved trials
ARMS - Rapidly Generated Multivirus-Specific CTLs for Prophylaxis & Treatment of EBV, CMV, Adenovirus, HHV6 & BK Virus
ARMS - Administration Of Rapidly Generated Multivirus-Specific Cytotoxic T-Lymphocytes For The Prophylaxis And Treatment Of EBV, CMV, Adenovirus, HHV6, And BK Virus Infections Post Allogeneic Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Houston Methodist Hospital
mi
from
Houston, TX
ARMS - Rapidly Generated Multivirus-Specific CTLs for Prophylaxis & Treatment of EBV, CMV, Adenovirus, HHV6 & BK Virus
ARMS - Administration Of Rapidly Generated Multivirus-Specific Cytotoxic T-Lymphocytes For The Prophylaxis And Treatment Of EBV, CMV, Adenovirus, HHV6, And BK Virus Infections Post Allogeneic Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Houston Methodist Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
ARMS - Rapidly Generated Multivirus-Specific CTLs for Prophylaxis & Treatment of EBV, CMV, Adenovirus, HHV6 & BK Virus
ARMS - Administration Of Rapidly Generated Multivirus-Specific Cytotoxic T-Lymphocytes For The Prophylaxis And Treatment Of EBV, CMV, Adenovirus, HHV6, And BK Virus Infections Post Allogeneic Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Texas Children's Hospital
mi
from
Houston, TX
ARMS - Rapidly Generated Multivirus-Specific CTLs for Prophylaxis & Treatment of EBV, CMV, Adenovirus, HHV6 & BK Virus
ARMS - Administration Of Rapidly Generated Multivirus-Specific Cytotoxic T-Lymphocytes For The Prophylaxis And Treatment Of EBV, CMV, Adenovirus, HHV6, And BK Virus Infections Post Allogeneic Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Texas Children's Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)
A Randomized, Open-Label, Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Los Angeles, CA
A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)
A Randomized, Open-Label, Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)
A Randomized, Open-Label, Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Palo Alto, CA
A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)
A Randomized, Open-Label, Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Palo Alto, CA
Click here to add this to my saved trials
A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)
A Randomized, Open-Label, Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Chicago, IL
A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)
A Randomized, Open-Label, Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)
A Randomized, Open-Label, Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Boston, MA
A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)
A Randomized, Open-Label, Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)
A Randomized, Open-Label, Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Hackensack, NJ
A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)
A Randomized, Open-Label, Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Hackensack, NJ
Click here to add this to my saved trials
A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)
A Randomized, Open-Label, Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
New York, NY
A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)
A Randomized, Open-Label, Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)
A Randomized, Open-Label, Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Pittsburgh, PA
A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)
A Randomized, Open-Label, Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)
A Randomized, Open-Label, Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Houston, TX
A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)
A Randomized, Open-Label, Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)
A Randomized, Open-Label, Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated:  12/31/1969
15
mi
from
Concord,
A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)
A Randomized, Open-Label, Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated: 12/31/1969
15
mi
from
Concord,
Click here to add this to my saved trials
Intravitreal Aflibercept Injection (IAI) for Presumed Ocular Histoplasmosis Syndrome
Treatment of CNV Secondary to Presumed Ocular Histoplasmosis With EYLEA 2.0mg (Intravitreal Aflibercept Injection)
Status: Enrolling
Updated:  12/31/1969
The Retina Institute
mi
from
Saint Louis, MO
Intravitreal Aflibercept Injection (IAI) for Presumed Ocular Histoplasmosis Syndrome
Treatment of CNV Secondary to Presumed Ocular Histoplasmosis With EYLEA 2.0mg (Intravitreal Aflibercept Injection)
Status: Enrolling
Updated: 12/31/1969
The Retina Institute
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
A Phase I Trial to Evaluate Safety and Immunogenicity of a Cytomegalovirus Peptide Vaccine Co-Injected With PF-03512676 Adjuvant in Recipients of Allogeneic Hematopoietic Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
City of Hope Medical Center
mi
from
Duarte, CA
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
A Phase I Trial to Evaluate Safety and Immunogenicity of a Cytomegalovirus Peptide Vaccine Co-Injected With PF-03512676 Adjuvant in Recipients of Allogeneic Hematopoietic Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
City of Hope Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma
Phase I Study of Romidepsin (ISTODAX®) Plus ICE for Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Status: Enrolling
Updated:  12/31/1969
M D Anderson Cancer Center
mi
from
Houston, TX
Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma
Phase I Study of Romidepsin (ISTODAX®) Plus ICE for Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Status: Enrolling
Updated: 12/31/1969
M D Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma
Phase I/II Study of Dasatinib in Recipients of Autologous Stem Cell Transplantation for Hematologic Malignancies.
Status: Enrolling
Updated:  12/31/1969
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma
Phase I/II Study of Dasatinib in Recipients of Autologous Stem Cell Transplantation for Hematologic Malignancies.
Status: Enrolling
Updated: 12/31/1969
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials